Covid-19 and Compulsory Licenses

Three countries—Chile, Ecuador and Israel has so far recommended compulsory licenses for patents relating to coronavirus.

Chile

On 17 March 2020, the Chilean Parliament approved a resolution asking the Chilean Government to declare that there is justification for compulsory licenses for vaccines, drugs, diagnostics, devices, supplies, and other technologies useful for the surveillance, prevention, detection, diagnosis and treatment of people infected by the coronavirus virus in Chile.

A translated copy of the resolution is available here: https://www.keionline.org/chilean-covid-resolution

Israel

On 19 March, Israel issued compulsory patent licenses related to lopinavir/ ritonavir, which is an HIV medicine currently being used by a number of countries in the treatment of Covid-19. The license allows the importation of lopinavir/ritonavir from a generic company. After the compulsory license was issued by Israel, on 23 March 2020, AbbVie has committed to not enforce its patents on lopinavir/ritonavir anywhere in the world.

Knowledge Ecology International provides a translation of the permit: https://www.keionline.org/wp-content/uploads/A-Permit-to-the-State-to-Exploit-an-Invention-Pursuant-to-Chapter-Six-Article-Three-of-the-Patents-Law-5727-1967.pdf

Ecuador

Lawmakers in Ecuador are looking to issue compulsory license for patents to combat covid-19 and ensure their citizens have access to any medical products requires. The National Assembly approved a resolution asking the Minister of Health to issue licenses that would allow the government to sidestep patents related to Covid-19 medical technologies.  

StatNews: Ecuador becomes the latest country to eye compulsory licensing for Covid-19 products available here: https://www.statnews.com/pharmalot/2020/03/23/ecuador-compulsory-licensing-covid19-coronavirus/

Knowledge Ecology International provides a translation of the permit: https://www.keionline.org/ecuador-CL-coronavirus-resolution

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s